Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01555463
First received: March 13, 2012
Last updated: January 25, 2015
Last verified: January 2015
  Purpose

The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.


Condition Intervention Phase
Papulopustular Rosacea
Drug: Azelaic acid foam, 15% (BAY39-6251)
Drug: Vehicle foam
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Static evaluation of overall severity of papulopustular rosacea at a given time: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. Therapeutic success is defined as an IGA score of clear or minimal.

  • Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF) [ Time Frame: Baseline and end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The mean (standard deviation) change from baseline in the inflammatory lesion count at the end of treatment is provided.


Secondary Outcome Measures:
  • Percent Change From Baseline in Inflammatory Lesion Count at End of Treatment (LOCF) [ Time Frame: Baseline and end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The mean (standard deviation) percentage change in inflammatory lesion count from baseline to end of study is provided.

  • Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Response at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Participants achieving a clear, minimal, or mild IGA at the end of treatment were considered as 'responder'. Participants with an IGA of moderate or severe at the end of treatment were considered as 'non-responder'. Participants who prematurely withdraw from study treatment because of lack of efficacy were coded as 'non-responders'. The percentage of responders is presented.

  • Grouped Changes From Baseline in Erythema Intensity Score at End of Treatment (LOCF) [ Time Frame: Baseline and end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Erythema was rated as: clear or almost clear; mild; moderate; or severe. For the assessment of the grouped change in erythema ratings, the baseline examination was used to group into 'improved', 'no change', or 'worsened'. A participant was considered to have an 'improved' erythema rating if the erythema rating was lower compared to the baseline rating, 'no change' if the rating was identical, and 'worsened' if the rating was higher. The percentage of participants in each of these categories is presented.

  • Percentage of Participants With Investigator's Global Assessment (IGA) Scores at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The IGA consists of 5 scores: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. The percentage of participants with each score at the end of treatment is provided.

  • Nominal Value of Inflammatory Lesion Count at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The mean (standard deviation) lesion count at the end of treatment is provided.

  • Percentage of Participants With Erythema Intensity Score at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The percentage of participants in each rating category of erythema (clear or almost clear; mild; moderate; severe) at the end of treatment is provided.

  • Grouped Changes From Baseline in Telangiectasia Intensity Score at End of Treatment (LOCF) [ Time Frame: Baseline and end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Telangiectasia was rated as: no; mild; moderate; or severe. At the end of study, a participant was considered to have an 'improved' telangiectasia rating if the telangiectasia rating was lower compared to the baseline rating, 'no change' if the rating was identical, and 'worsened' if the rating was higher. The percentage of participants in each category is presented.

  • Percentage of Participants With Facial Skin Color Rating at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Facial skin color (as compared with skin outside the treatment area) was rated as: normal; barely visible skin lightening; mild skin lightening; moderate skin lightening; severe skin lightening. The percentage of participants in each category of facial skin color at the end of study is presented.

  • Participants' Global Assessment of Treatment Response at End of Treatment [ Time Frame: At end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    At the end of treatment, participants assessed the change of papulopustular rosacea from baseline (how it looked, felt, appeared to others) as excellent improvement, good improvement, fair improvement, no improvement, or worse. The number of participants in each category of this assessment is presented.

  • Participants' Global Assessment of Tolerability at End of Treatment [ Time Frame: At end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    At the end of treatment, participants provided their opinion on local tolerability of the investigational product as excellent, good, acceptable despite minor irritation, less acceptable due to continuous irritation, non-acceptable, or no opinion. The number of participants in each category of this assessment is presented.

  • Participants' Opinion on Cosmetic Acceptability at End of Treatment [ Time Frame: At end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    At the end of treatment, participants provided their opinion on cosmetic acceptability of the investigational product as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.

  • Participants' Opinion on Practicability of Product Use in Facial Areas Next to the Hairline at End of Treatment [ Time Frame: At end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    At the end of treatment, participants provided their opinion on the practicability of the use of the investigational product in facial areas next to the hairline as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.

  • Change From Baseline in Rosacea Quality of Life (RosaQoL) Questionnaire at End of Treatment - Overall Quality of Life Score [ Time Frame: Baseline and end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    The Rosacea Quality of Life (RosaQoL) is a questionnaire to evaluate the effect of rosacea on a participant's quality of life. Each of the 21 items in this questionnaire asks about the frequency with which a particular aspect of living with rosacea affects the participant: possible responses for each item are "never" (score=1), "rarely" (score=2), "sometimes" (score=3), "often" (score=4), or "all the time" (score=5). The overall score is the sum of the results from all 21 questions, with possible scores ranging from 21 (best) to 105 (worst); the higher the score, the more quality of life is impaired. The mean (standard deviation) of the change, defined as end of treatment overall score minus baseline overall score, is presented.

  • Number of Participants With Change From Baseline in Dermatology Life Quality Index (DLQI) Questionnaire at End of Treatment - Overall Score [ Time Frame: Baseline and end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    The Dermatology Life Quality Index (DLQI) is a questionnaire consisting of a set of 10 questions that evaluate the degree to which the participant's skin has affected certain behaviors and quality of life over the past week. Possible responses to each question are: "very much" (question 7: "yes") (score=3), "a lot" (score=2), "a little" (score=1), or "not at all"/"not relevant" (score=0). The DLQI overall score is the sum of the results from all 10 questions, with possible scores ranging from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The number of participants with score changes (end of treatment - baseline) in DLQI overall score from baseline to end of treatment <=-5 and >-5 are presented.

  • Change From Baseline in EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) at End of Treatment [ Time Frame: Baseline and end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    The EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) is a standardized instrument for use as a measure of health outcome. The EQ-VAS asks for a judgment of the overall health status assessed by the participant her/himself. The 20-cm visual analog scale (VAS) has endpoints labeled "best imaginable health state" and "worst imaginable health state" that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day; higher scores indicate a better health state. The median (range) of the change, defined as EQ-VAS at end of treatment minus EQ-VAS at baseline, is presented.

  • Change From Baseline in Index Value at End of Treatment [ Time Frame: Baseline and end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    The EuroQol Group Questionnaire-5 Dimensions-5 Levels (EQ-5D-5L) is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is used to assess the level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension is evaluated using 5 levels: "no problems" (level 1), "slight problems" (level 2), "moderate problems" (level 3), "severe problems" (level 4), and "extreme problems" (level 5). A scoring formula developed by EuroQol Group calculates a single index value from the results from all 5 domains along a continuum of 0 (death) to 1 (full health). The median (range) change, defined as the index value at end of treatment minus the index value at baseline, is presented.


Enrollment: 961
Study Start Date: September 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Azelaic acid foam, 15% (BAY39-6251)
0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
Drug: Azelaic acid foam, 15% (BAY39-6251)
Azelaic acid twice daily topical application
Placebo Comparator: Vehicle foam
0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
Drug: Vehicle foam
twice daily topical application

Detailed Description:

To determine the efficacy of AzA foam, 15% compared to vehicle topically applied twice daily in papulopustular rosacea evaluated by therapeutic success rate according to Investigators Global Assessment (IGA) and change in inflammatory lesion count from baseline to end of treatment.

Evaluation of all adverse events will be covered in Adverse Events section.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of papulopustular rosacea
  • Free of any clinically significant disease, which could interfere with the study
  • Male or female subject aged ≥ 18 years
  • Willingness of subject to follow all study procedures
  • Signed written informed consent before any study-related activities are carried out

Exclusion Criteria:

  • Subjects who are known to be non-responders to azelaic acid
  • Presence of dermatoses that might interfere with rosacea diagnosis
  • Ocular rosacea; phymatous rosacea; subjects with plaque-type rosacea lesions, papulopustular rosacea that requires systemic treatment
  • Topical use of any prescription or non-prescription medication to treat rosacea within 6 weeks prior to randomization and throughout the study
  • Systemic use of any prescription or non-prescription medication to treat rosacea (Retinoids within 6 months, Tetracycline within 2 months, Corticosteroids, erythromycin, azithromycin, and/or metronidazole within 4 weeks) prior to randomization and throughout the study
  • Facial laser surgery for telangiectasia (or other conditions) within 6 weeks prior to randomization
  • Known hypersensitivity to any ingredients of the investigational product formulation
  • Participation in another clinical research in parallel or within the last 4 weeks before randomization in this study
  • Any condition or therapy that in the investigator's opinion may pose a risk to the subject or that could interfere with any evaluation in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01555463

  Show 49 Study Locations
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01555463     History of Changes
Other Study ID Numbers: 16080, 1401846
Study First Received: March 13, 2012
Results First Received: December 28, 2014
Last Updated: January 25, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Bayer:
Rosacea

Additional relevant MeSH terms:
Rosacea
Skin Diseases
Azelaic acid
Antineoplastic Agents
Dermatologic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on February 27, 2015